Evidence map›Paper›PMID 32404110›Full record

ArticleMalaria journal2020

Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum.

Megan R Ansbro, Christopher G Jacob, Roberto Amato, Mihir Kekre, Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, Olivo Miotto, Rick M Fairhurst, Thomas E Wellems and 1 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. AmBio · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Temporal and spatial dynamics ofbioRxiv : the preprint server for biology · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Megan R AnsbroWellcome Sanger Institute, Hinxton, UK. ma20@sanger.ac.uk.ORCID http://orcid.org/0000-0002-7131-1610
Christopher G JacobWellcome Sanger Institute, Hinxton, UK. cj9@sanger.ac.uk.
Roberto AmatoWellcome Sanger Institute, Hinxton, UK.
Mihir KekreWellcome Sanger Institute, Hinxton, UK.
Chanaki AmaratungaLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Sokunthea SrengNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
Seila SuonNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
Olivo MiottoWellcome Sanger Institute, Hinxton, UK.
Rick M FairhurstLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Thomas E WellemsLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Dominic P KwiatkowskiWellcome Sanger Institute, Hinxton, UK.
Wellcome Sanger Institute · GBNational Institutes of Health · USCambodia National Malaria Center · KHCentre for Human Genetics · GB

Funding

Malaria Drug Resistance and Disease VirulenceZIAAI000483 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2025
$24.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008620 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 1999 to 2023
$8.1M
Medical Research Council MR/M006212/1NIGMS NIH HHS T32 GM008620Wellcome Trust 090770/Z/09/ZWellcome Trust 098051Wellcome Trust 204911/Z/16/ZWellcome Trust 206194
6 · The paper itself

Abstract

backgroundLong regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of Plasmodium falciparum malaria. Recently, resistance to the artemisinin combination therapy partner drug piperaquine has been observed in multiple locations across Southeast Asia. Genetic studies have identified single nucleotide polymorphisms as well as copy number variations in the plasmepsin 2 and plasmepsin 3 genes, which encode haemoglobin-degrading proteases that associate with clinical and in vitro piperaquine resistance.

resultsTo accurately and quickly determine the presence of copy number variations in the plasmepsin 2/3 genes in field isolates, this study developed a quantitative PCR assay using TaqMan probes. Copy number estimates were validated using a separate SYBR green-based quantitative PCR assay as well as a novel PCR-based breakpoint assay to detect the hybrid gene product. Field samples from 2012 to 2015 across three sites in Cambodia were tested using DNA extracted from dried blood spots and whole blood to monitor the extent of plasmepsin 2/3 gene amplifications, as well as amplifications in the multidrug resistance transporter 1 gene (pfmdr1), a marker of mefloquine resistance. This study found high concordance across all methods of copy number detection. For samples derived from dried blood spots, a success rate greater than 80% was found in each assay, with more recent samples performing better. Evidence of extensive plasmepsin 2/3 copy number amplifications was observed in Pursat (94%, 2015) (Western Cambodia) and Preah Vihear (87%, 2014) (Northern Cambodia), and lower levels in Ratanakiri (16%, 2014) (Eastern Cambodia). A shift was observed from two copies of plasmepsin 2 in Pursat in 2013 to three copies in 2014-2015 (25% to 64%). Pfmdr1 amplifications were absent in all samples from Preah Vihear and Ratanakiri in 2014 and absent in Pursat in 2015.

conclusionsThe multiplex TaqMan assay is a robust tool for monitoring both plasmepsin 2/3 and pfmdr1 copy number variations in field isolates, and the SYBR-green and breakpoint assays are useful for monitoring plasmepsin 2/3 amplifications. This study shows increasing levels of plasmepsin 2 copy numbers across Cambodia from 2012 to 2015 and a complete reversion of multicopy pfmdr1 parasites to single copy parasites in all study locations.

Indexed as

AntimalarialsAspartic Acid EndopeptidasesDNA Copy Number VariationsDrug ResistanceGenetic TechniquesPiperazinesPlasmodium falciparumQuinolinesAntimalarialsAspartic Acid EndopeptidasespiperaquinePiperazinesplasmepsinQuinolinesCambodiaCopy numberMalariaPiperaquinePlasmepsinqPCR

Identifiers

PMID32404110
PMCPMC7218657
OpenAlexW3026367922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.